Company Snapshot

Overview

CLINUVEL (ASX: CUV; ADR Level 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA.

SCENESSE®, PRÉNUMBRA®, and NEURACTHEL® are registered trademarks of CLINUVEL.

Company snapshot

Facts ASX Listed 2001
Shares on Issue 49,410,338
Conditional performance rights 2,630,193
Locations Melbourne, Australia Company headquarters
Zug, Switzerland Swiss operational office
Dublin, Ireland EU operational office
Monaco Monaco operational office
Leatherhead, UK UK operational office
Singapore VALLAURIX Research, Development & Innovation Centre
Burlingame, US US operational office
Stock Listings ASX CUV
Börse Frankfurt UR9
Level 1 ADR CLVLY
Key Financial Statistics
FY June 2023
Total revenues A$83.0m
Net profit A$30.6m
Net cash increase A$33.6m
Cash A$156.8m
Total assets A$193.7m
Equity A$164.6m
Products SCENESSE® (afamelanotide 16mg implant) First-in-class photoprotective and repigmentation drug with EMA, US FDA and Australian TGA approvals for rare disease EPP. Phase IIb trial completed in Singapore for vitiligo. Trial programs for stroke and DNA Repair.
CUV9900 An alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development.
Parvysmelanotide (VLRX001) An alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development.
PRÉNUMBRA® PRÉNUMBRA® is a liquid (non-solid) injectable formulation of afamelanotide designed for administration by a healthcare professional and intended to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone.
NEURACTHEL® (ACTH) Translating its expertise in melanocortins and formulation development, CLINUVEL is commercialising NEURACTHEL® (adrenocorticotropic hormone; ACTH) in multiple dosage forms for patients in need of medical treatment. ACTH is a naturally occurring hormone which plays an important role in the production of cortisol, enabling the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism.
People Dr Philippe Wolgen CEO, Managing Director
Brenda Shanahan Non-Executive Director
Dr Karen Agersborg Non-Executive Director
Susan Smith Non-Executive Director
Professor Jeffrey V. Rosenfeld Non-Executive Chair
Darren Keamy CFO, Company Secretary
Dr Dennis Wright Chief Scientific Officer
Lachlan Hay Director of Global Operations
Go To Top